World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
48
Citations
9639
World Ranking
4418
National Ranking
2006

Daniel A. Scott publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Daniel A. Scott sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 157 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Daniel A. Scott D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel A. Scott sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 48 D-Index — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Daniel A. Scott is affiliated with Pfizer in the United States. Their research primarily focuses on medicine, with a significant emphasis on epidemiology, where they have contributed the majority of their work. Other subfields include public health, environmental and occupational health, immunology, pulmonary and respiratory medicine, and microbiology.

The scientist's work concentrates on topics related to pneumonia and respiratory infections, respiratory viral infections research, and Pneumocystis jirovecii pneumonia detection and treatment. Additional topics include influenza virus research studies, immunodeficiency and autoimmune disorders, bacterial infections and vaccines, as well as neonatal and maternal infections.

Frequent co-authors in their publications include William C. Gruber, Wendy Watson, Yahong Peng, Kathrin U. Jansen, and Ingrid L. Scully.

Publications by Daniel A. Scott have appeared in various venues, with the highest number in Open Forum Infectious Diseases. Other prominent journals include Vaccine, Human Vaccines & Immunotherapeutics, The Pediatric Infectious Disease Journal, and Clinical Infectious Diseases.

Recent notable papers include:

  • Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age, 2020, Clinical Infectious Diseases
  • Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years, 2021, Clinical Infectious Diseases
  • Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study, 2022, New England Journal of Medicine
  • Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial, 2020, The Lancet Infectious Diseases
  • Potential for Maternally Administered Vaccine for Infant Group B Streptococcus, 2023, New England Journal of Medicine

Best Publications

  • Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

    Marc J.M. Bonten;Susanne M. Huijts;Marieke Bolkenbaas;Chris Webber

  • Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial

    Ron Dagan;Scott Patterson;Christine Juergens;David Greenberg

  • Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

    Sylvia H Yeh;Alejandra Gurtman;David C Hurley;Stan L Block

  • Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

    Lisa A. Jackson;Alejandra Gurtman;Martin van Cleeff;Kathrin U. Jansen

  • Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

    Lisa A. Jackson;Alejandra Gurtman;Kathryn Rice;Karlis Pauksens

  • Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine

    Kristina A Bryant;Stan L Block;Sherryl A Baker;William C Gruber

  • Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

    Dorothee M. Kieninger;Kathrin Kueper;Katrin Steul;Christine Juergens

  • Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously

    Fernando Güereña-Burgueño;Eric R. Hall;David N. Taylor;Frederick J. Cassels

  • Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

    Susanna Esposito;Susan Tansey;Allison Thompson;Ahmad Razmpour

  • Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

    Lisa A. Jackson;Alejandra Gurtman;Martin van Cleeff;Robert W. Frenck

  • Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

    Richard N. Greenberg;Alejandra Gurtman;Robert W. Frenck;Cynthia Strout

  • Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.

    Unknown

  • Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults☆☆☆

    Daniel A. Scott;Steven F. Komjathy;Branda T. Hu;Sherryl Baker

  • Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

    Unknown

  • Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.

    Donald Hurley;Carl Griffin;Mariano Young;Daniel A Scott

  • Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

    David R. Tribble;Shahida Baqar;Daniel A. Scott;Michael L. Oplinger

  • Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.

    Matthew D. Snape;Chaam L. Klinger;Elvis D. Daniels;Tessa M. John

  • Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

    Catherine Cordonnier;Per Ljungman;Christine Juergens;Johan Maertens

  • Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.

    Judith Absalon;Nathan Segall;Stan L Block

  • Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.

    Allison Thompson;Erik Lamberth;Joseph Severs;Ingrid Scully

  • Vaccines against Campylobacter jejuni.

    Daniel A. Scott

  • IS1414, an Escherichia coli Insertion Sequence with a Heat-Stable Enterotoxin Gene Embedded in a Transposase-Like Gene

    Annette McVeigh;Annette McVeigh;Alessio Fasano;Daniel A. Scott;Sandra Jelacic

  • Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.

    William C. Gruber;Daniel A. Scott;Emilio A. Emini

Frequent Co-Authors

William C. Gruber
William C. Gruber Pfizer (United States)
Emilio A. Emini
Emilio A. Emini Pfizer (United States)
Kathrin U. Jansen
Kathrin U. Jansen Pfizer (United States)
Robert W. Frenck
Robert W. Frenck Cincinnati Children's Hospital Medical Center
Ron Dagan
Ron Dagan Ben-Gurion University of the Negev
Marc J. M. Bonten
Marc J. M. Bonten Utrecht University
David Greenberg
David Greenberg Ben-Gurion University of the Negev
Noga Givon-Lavi
Noga Givon-Lavi Ben-Gurion University of the Negev
Diederick E. Grobbee
Diederick E. Grobbee Utrecht University
Paul T. Heath
Paul T. Heath St George's, University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Immunology in the USA opens doors to various healthcare careers, including specialized nursing roles. For those interested in mental health, exploring the best online pmhnp programs can lead to rewarding clinical placements and valuable hands-on experience.

Cost is often a major consideration. Prospective students seeking budget-friendly options may find a list of cheap psych np programs helpful as they plan their education without compromising quality.

Career advancement paths such as obtaining a Doctor of Nursing Practice (DNP) degree can significantly impact earnings. Understanding the doctor of nursing practice salary by state allows professionals to make informed decisions about where to work post-graduation.

For nurses currently working as Family Nurse Practitioners, specialized training through acnp programs enables a transition into acute care, broadening clinical expertise and expanding career opportunities.

Best Scientists Citing Daniel A. Scott

Trending Scientists

Recently Published Articles